June 18, 2008 – Naviscan PET Systems released new clinical data using the PEM Flex scanner in breast cancer management, the PEM Flex Solo II is a commercially available, FDA-cleared scanner that utilizes PET technology for the breast application as positron emission mammography.
Results presented from an independent study for 136 participants comparing the accuracy of PEM and MRI in the presurgical planning of breast cancer patients indicated the PEM technology is more sensitive than MRI in detecting the smallest cancers. PEM demonstrated 91 percent sensitivity in ductal carcinoma in situ (DCIS) compared to 83 percent with MRI and better sensitivity in cancers less than 5 mm in size. PEM also detected a two-millimeter DCIS case shown to be negative on MRI.
For more information: www.naviscanpet.com
October 19, 2026 
